BRPI0820177B8 - métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas - Google Patents

métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas

Info

Publication number
BRPI0820177B8
BRPI0820177B8 BRPI0820177A BRPI0820177A BRPI0820177B8 BR PI0820177 B8 BRPI0820177 B8 BR PI0820177B8 BR PI0820177 A BRPI0820177 A BR PI0820177A BR PI0820177 A BRPI0820177 A BR PI0820177A BR PI0820177 B8 BRPI0820177 B8 BR PI0820177B8
Authority
BR
Brazil
Prior art keywords
methods
protein extract
producing
cells
fixed
Prior art date
Application number
BRPI0820177A
Other languages
English (en)
Inventor
P Malick Adrien
S Ferguson Carrie
Mantlo John
H Bruton Jefferey
L Rosales Julie
J Beadenkopf Robert
M Crews Virginia
Original Assignee
Arbor Vita Corp
Becton Dickinson Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbor Vita Corp, Becton Dickinson Co filed Critical Arbor Vita Corp
Publication of BRPI0820177A2 publication Critical patent/BRPI0820177A2/pt
Publication of BRPI0820177B1 publication Critical patent/BRPI0820177B1/pt
Publication of BRPI0820177B8 publication Critical patent/BRPI0820177B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4044—Concentrating samples by chemical techniques; Digestion; Chemical decomposition
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas, e, sistema para produzir um extrato de proteína. são fornecidos métodos para produzir um extrato de proteína de células, tais como células ou amostras celulares contendo proteínas virais. em termos gerais, os métodos podem envolver: aumentar o ph das células par um de pelo menos cerca de ph 10,0 para produzir uma composição intermediária, e então na presença de um detergente não -iônico tal como um polioxietileno-alqui-éter,neutralizar o ph da composição intermediária para produzir o extrato de proteína.tais métodos podem ser usados conjuntamente com métodos para detectar uma ou mais proteínas alvo em uma amostra, tais como proteínas virais. sistemas, kits e composições para praticar os presentes métodos também são fornecidos.
BRPI0820177A 2007-11-14 2008-11-14 métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas BRPI0820177B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/985547 2007-11-14
US11/985,547 US9207240B2 (en) 2007-11-14 2007-11-14 Method of efficient extraction of protein from cells
PCT/US2008/083707 WO2009065091A1 (en) 2007-11-14 2008-11-14 Method of efficient extraction of protein from cells

Publications (3)

Publication Number Publication Date
BRPI0820177A2 BRPI0820177A2 (pt) 2014-11-04
BRPI0820177B1 BRPI0820177B1 (pt) 2019-07-02
BRPI0820177B8 true BRPI0820177B8 (pt) 2021-07-27

Family

ID=40624059

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820177A BRPI0820177B8 (pt) 2007-11-14 2008-11-14 métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas

Country Status (9)

Country Link
US (2) US9207240B2 (pt)
EP (1) EP2222838B1 (pt)
JP (1) JP5787519B2 (pt)
CN (2) CN107629109A (pt)
AU (1) AU2008322473B2 (pt)
BR (1) BRPI0820177B8 (pt)
CA (1) CA2705765C (pt)
ES (1) ES2456341T3 (pt)
WO (1) WO2009065091A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007134252A1 (en) * 2006-05-11 2007-11-22 Becton, Dickinson And Company Method of protein extraction from cells
US20100003704A1 (en) * 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
WO2011028887A2 (en) 2009-09-03 2011-03-10 Becton, Dickinson And Company Methods and compositions for direct chemical lysis
US8658417B2 (en) * 2009-09-15 2014-02-25 Qiagen Gaithersburg, Inc. Multiple-input analytical system
US8994937B2 (en) 2012-04-18 2015-03-31 Hewlett-Packard Development Company, L.P. Surface enhanced Raman spectroscopy calibration curve generating systems
US9680916B2 (en) 2013-08-01 2017-06-13 Flowtraq, Inc. Methods and systems for distribution and retrieval of network traffic records
JP6397224B2 (ja) * 2014-06-04 2018-09-26 田中貴金属工業株式会社 免疫学的測定試薬におけるプロゾーン現象の解消法
CN104237198A (zh) * 2014-07-31 2014-12-24 中国人民解放军第二军医大学 一种判定中药材或中药饮片是否染色的方法
EP3465217A1 (en) * 2016-05-31 2019-04-10 Roche Diagnostics GmbH Method for serological detection of viral antigens
CN107621462B (zh) * 2016-07-13 2020-03-31 王志伟 一种组织透明化液sut及其制备和应用
WO2018130072A1 (zh) * 2017-01-12 2018-07-19 厦门大学 稳定呼吸道合胞病毒融合蛋白的方法
WO2019121235A1 (en) * 2017-12-22 2019-06-27 Basf Plant Science Company Gmbh Method and means for an isolation of membrane-bound proteins from a biological sample, preferably processed plant seed meal
JP7267548B2 (ja) * 2019-04-24 2023-05-02 株式会社ニップン トマト黄化葉巻ウイルス（ｔｙｌｃｖ）の免疫学的診断法
CN112213164A (zh) * 2019-07-12 2021-01-12 温州医科大学附属第一医院 一种总蛋白提取试剂盒及提取方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3546334A (en) * 1965-05-21 1970-12-08 Lerner Lab Inc Composition for fixing and protecting a smear of body cells and method of applying same
US3303038A (en) * 1965-07-29 1967-02-07 Ethicon Inc Process of forming collagen articles and dispersions
JPS5535088B2 (pt) * 1971-09-10 1980-09-11
US4578282A (en) * 1982-02-04 1986-03-25 Harrison James S Composition for diagnostic reagents
US4766065A (en) 1984-08-23 1988-08-23 Becton Dickinson And Company Detection of cell membrane protein
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
US4857300A (en) * 1987-07-27 1989-08-15 Cytocorp, Inc. Cytological and histological fixative formulation and methods for using same
US5132205A (en) * 1988-10-07 1992-07-21 Eastman Kodak Company High ph extraction composition and its use to determine a chlamydial, gonococcal or herpes antigen
US5047325A (en) 1988-10-07 1991-09-10 Eastman Kodak Company Wash solution containing a cationic surfactant and its use in chlamydial and gonococcal determinations
US5081010A (en) 1989-02-09 1992-01-14 Eastman Kodak Company Extraction composition, test kit and their use to extract or determine herpes simplex viral antigen
US5104640A (en) * 1989-03-17 1992-04-14 Wescor, Inc. Fixative composition for fixing blood smears to slides
US5256571A (en) * 1991-05-01 1993-10-26 Cytyc Corporation Cell preservative solution
US5196182A (en) * 1991-05-08 1993-03-23 Streck Laboratories, Inc. Tissue fixative
US5773277A (en) * 1992-06-26 1998-06-30 Seikagaku Kogyo Kabushiki Kaisha Crystalline chondroitinase isolated from Proteus vulgaris ATCC 6896
US5432056A (en) * 1993-11-15 1995-07-11 Ventana Medical Systems, Inc. Bisulfite-based tissue fixative
US5658749A (en) * 1994-04-05 1997-08-19 Corning Clinical Laboratories, Inc. Method for processing mycobacteria
US5620869A (en) * 1995-09-28 1997-04-15 Becton, Dickinson And Company Methods for reducing inhibition of nucleic acid amplification reactions
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
US20050019841A1 (en) * 1999-05-14 2005-01-27 Arbor Vita Corporation Modulation of signaling pathways
US20050037969A1 (en) * 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
US20060148711A1 (en) * 1999-05-14 2006-07-06 Arbor Vita Corporation Molecular interactions in neurons
US6488671B1 (en) * 1999-10-22 2002-12-03 Corazon Technologies, Inc. Methods for enhancing fluid flow through an obstructed vascular site, and systems and kits for use in practicing the same
UA76708C2 (uk) * 1999-12-08 2006-09-15 Сінгента Патисипейшонс Аг Антитіло, яке застосовується в імунологічному аналізі зразка для визначення неонікотиноїдного інсектициду, білковий кон'югат для одержання антитіла, спосіб визначення концентрації неонікотиноїдного інсектициду в зразку та набір для визначення кількості неонікотиноїдного інсектициду
US6337189B1 (en) * 2000-02-08 2002-01-08 Streck Laboratories, Inc. Fixative system, method and composition for biological testing
US6436662B1 (en) * 2000-04-04 2002-08-20 Digene Corporation Device and method for cytology slide preparation
WO2002007751A1 (en) * 2000-07-25 2002-01-31 Axcell Biosciences Corporation Identification and isolation of novel polypeptides having pdz domains and methods of using same
US20030175852A1 (en) * 2000-09-15 2003-09-18 Kalra Krishan L Ehancement of in situ hybridization
US7312041B2 (en) * 2001-02-16 2007-12-25 Arbor Vita Corporation Methods of diagnosing cervical cancer
MXPA03011455A (es) 2001-06-22 2004-04-05 Hoffmann La Roche Complejo soluble que comprende glucoproteina de superficie retroviral.
US20050032105A1 (en) * 2001-10-12 2005-02-10 Bair Robert Jackson Compositions and methods for using a solid support to purify DNA
EP1507148B1 (en) 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
EP1537415B1 (en) 2002-09-09 2008-12-17 Arbor Vita Corporation Methods of diagnosing cervical cancer
AU2003298594A1 (en) * 2002-11-01 2004-06-07 Promega Corporation Cell lysis compositions, methods of use, apparatus, and kit
WO2005058933A1 (en) * 2003-12-16 2005-06-30 Gentra Systems, Inc. Formulations and methods for denaturing proteins
AU2004308964B2 (en) * 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
EP1743032A4 (en) * 2004-04-15 2007-09-05 Allied Biotech Inc METHODS AND APPARATUS FOR DETECTING VIRAL INFECTIONS
MXPA06014480A (es) * 2004-06-09 2007-03-21 Pathogen Removal And Diagnosti Particulas incluidas en un substrato poroso para la remocion de analitos objetivo de una muestra.
WO2007134252A1 (en) 2006-05-11 2007-11-22 Becton, Dickinson And Company Method of protein extraction from cells
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells

Also Published As

Publication number Publication date
US9207240B2 (en) 2015-12-08
CN101910400A (zh) 2010-12-08
EP2222838B1 (en) 2014-01-22
US9995745B2 (en) 2018-06-12
AU2008322473B2 (en) 2014-07-03
EP2222838A4 (en) 2011-01-05
CN107629109A (zh) 2018-01-26
BRPI0820177A2 (pt) 2014-11-04
CA2705765A1 (en) 2009-05-22
ES2456341T3 (es) 2014-04-22
AU2008322473A1 (en) 2009-05-22
US20160216258A1 (en) 2016-07-28
CA2705765C (en) 2018-12-11
JP2011503208A (ja) 2011-01-27
WO2009065091A1 (en) 2009-05-22
JP5787519B2 (ja) 2015-09-30
CN101910400B (zh) 2017-06-27
BRPI0820177B1 (pt) 2019-07-02
EP2222838A1 (en) 2010-09-01
US20090123910A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
BRPI0820177B8 (pt) métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas
Fafián-Labora et al. Influence of age on rat bone-marrow mesenchymal stem cells potential
BR112012009289A8 (pt) Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BR112018008061A2 (pt) métodos para a cultura de células e kits e aparelhos para os mesmos
BR112015014751A2 (pt) anticorpos anti-tau humanos
AR080942A1 (es) Produccion de proteinas heteromultimericas
BR112015031639A2 (pt) integração alvo
BR112014019277A8 (pt) Populações de células-tronco estromais, tecidos, métodos de isolamento de células-tronco estromais, método de obtenção de tecido, ensaio e método para condução de ensaio e composição farmacêutica
BR112015022971A2 (pt) métodos de fabricação para controlar o teor de lisina c-terminal, galactose e ácido siálico em proteínas recombinantes
BR112018002214A2 (pt) ?métodos para cultivar células e para produzir uma proteína, meios de cultura de células cho e de batelada alimentada e/ou alimentação, e, alimentação de cultura de células cho?
BR112015019066A2 (pt) Anticorpos humanos para proteína f do vírus respiratório sincicial e métodos de uso dos mesmos
BRPI0911699B8 (pt) vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
Barjaktarovic et al. Integrative proteomic and microRNA analysis of primary human coronary artery endothelial cells exposed to low-dose gamma radiation
BR112013009376A2 (pt) métodos para determinar isótipos de anticorpos antifármacos
BR112013000515A2 (pt) método para prodduzir um composição de fator von willebrand recombinante (rvwf), sobrenadante de cultura de célula, e, composição do fator von willebrand recombinante (rvwf)
AR048989A1 (es) Metodos y composiciones para modular la expresion en plantas
BR112014023869A2 (pt) proteínas nutritivas carregadas e métodos
EA201991976A1 (ru) Метаболически оптимизированная клеточная культура
BR112021025130A2 (pt) Reagentes e métodos para replicação, transcrição e tradução em organismos semissintéticos
WO2007018671A3 (en) Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
BRPI1011940B8 (pt) método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero
BR112014020513A2 (pt) Métodos e sistemas para amplificação de sinal de bioensaios
BR112021019701A2 (pt) Anticorpos multiespecíficos para antígeno de câncer de bomba de efluxo e composições, reagentes, kits e métodos relacionados aos mesmos
BRPI0410562A (pt) molécula recombinante e veìculo para expressão, liberação e purificação de polipeptìdeos alvo
BR112012012911A2 (pt) métodos para triar uma molécula capaz de ligação a cd4, para produzir uma composição terapêutica, para triar um anticorpo ou fragmento de anticorpo, in vitro para a ativação de células t regulatórias cd4+cd25+, para tratar um indivíduo, e para triar a presença de células regulatórias t cd4+cd25+ em uma amostra, composição terapêutica, anticorpo ou fragmento de anticorpo, peptídeo isolado, mimótopo de um peptídeo isolado, ácido nucleico, vetor, célula hospedeira ou hibridoma, usos de um anticorpo ou fragmento de anticorpo, do peptídeo isolado e de uma célula t regulatória cd4+cd25+, célula t regulatória cd4+cd25+, e, kit.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 1/36 (2006.01), C12N 5/071 (2010.01)

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2644 DE 08-09-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.